|This article relies too much on references to primary sources. (April 2007) (Learn how and when to remove this template message)|
The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".
Anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer. Doxorubicin, the first anthracycline to gain approval, has demonstrated efficacy in a wide variety of cancers including breast cancer, lung cancer, sarcomas, and lymphomas. However, doxorubicin is associated with side effects such as myelosuppression, gastrointestinal disorders, mucositis, stomatitis, cumulative cardiotoxicity and extravasation.
CytRx plans to expand its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites.
The corporate website is http://www.cytrx.com/aldoxorubicin
Steven Arthur Kriegsman is the President and CEO.
Aldoxorubicin (formerly INNO-206) is a tumor-targeted doxorubicin conjugate. Specifically, it is the (6-Maleimidocaproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin (DOXO) attached to an acid sensitive linker (EMCH).
Completed preclinical and clinical trials (see below) indicate that this novel agent has attributes that improve on native doxorubicin including reduction of adverse events, improvement in efficacy and the ability to reach the tumor more quickly. CytRx holds the exclusive worldwide rights to aldoxorubicin.
In 2014 CytRx was involved in a stock promotion scheme, paying DreamTeamGroup US$65,000 to write at least 13 articles that appeared on Seeking Alpha, Forbes.com, Motley Fool, and Cheat Sheet. The articles carried no conflict of interest disclosure, and were reviewed and edited by CytRx management. The stock price doubled following the articles. The articles and author profile pages (including pseudonyms) were removed after investigation by CNNMoney. A class action lawsuit has been filed against CytRx.
The events leading to CytRx lawsuits were revealed by a Seeking Alpha author named Richard Pearson who was shorting the CytRx company stock and the "short attack" was revealed by another Seeking Alpha author PhD. who wrote about the science of aldoxorubicin and revealed the motives behind Richard Pearson's article to short the company's stock. The second Seeking Alpha article pointed to a financial motive for the negative article and that the author Richard Pearson took a short position in CytRx company stock 3 days before he published his article about CytRx. http://seekingalpha.com/instablog/4519051-nir-etkovitz/2756043-behind-the-short-are-investors-of-cytrx-that-shallow
- Galena Biopharma, a former subsidiary of CytRx
- "At financial news sites, stock promoters make inroads - The Term Sheet: Fortune's deals blogTerm Sheet". CNN. Retrieved 20 April 2014.
- "CytRx Corporation (CYTR) news: Behind The Scenes With Dream Team, CytRx And Galena - Seeking Alpha". Seeking Alpha. Retrieved 20 April 2014.
- "Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors of the May 13, 2014 Deadline to File for Lead Plaintiff in the Securities Fraud Class Action Against CytRx Corporation -- CYTR - MarketWatch". MarketWatch. Retrieved 20 April 2014.